Progress of cytokine release syndrome in children CAR-T cell therapy
10.3760/cma.j.issn.1673-4408.2022.12.001
- VernacularTitle:儿童CAR-T细胞治疗中细胞因子释放综合征的研究进展
- Author:
Jing YANG
1
;
Benshang LI
Author Information
1. 上海交通大学医学院附属上海儿童医学中心血液肿瘤科 200127
- Keywords:
Children;
Acute lymphoblastic leukemia;
Chimeric antigen receptor T-cell;
Cytokine release syndrome
- From:
International Journal of Pediatrics
2022;49(12):793-798
- CountryChina
- Language:Chinese
-
Abstract:
As a disruptive therapeutic technique, chimeric antigen receptor T-cell (CAR-T)immunotherapy has achieved a revolutionary breakthrough in pediatric patients with relapsed/refractory acute lymphoblastic leukemia(ALL). Using genetic engineering technology, T lymphocytes can be modified to express CAR on the surface, which then target tumor-specific antigens and exert cytotoxic effects against tumor cells.However, CAR-T therapy may cause some serious adverse reactions, of which the most common and noticeable is cytokine release syndrome(CRS). Inappropriate medical management of CRS will lead to severe complications and can be even life-threating.In this review, we mainly discuss the progress of CRS in the CAR-T therapy of children ALL from the aspects of the mechanism, clinical manifestations, grading systems and clinical treatment.
